TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Necchi, A; Guerrero-Ramos, F; Crispen, PL; Herrera-Imbroda, B; Garje, R; Powles, T; Peyton, CC; Pradere, B; Ku, JH; Shore, N; Bögemann, M; Preston, MA; Xylinas, E; Llano, CSD; Hasan, M; Stitou, H; Bhanvadia, S; Sweiti, H; Psutka, S – 2025 –...

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study – EUROPEAN UROLOGY ONCOLOGY

Romero-Laorden, N; Lorente, D; de Velasco, G; Lozano, R; Herrera, B; Puente, J; López, PP; Medina, A; Almagro, E; Gonzalez-Billalabeitia, E; Villla-Guzman, JC; González-del-Alba, A; Borrega, P; Laínez, N; Fernández-Freire, A; Hernández, A; Rodriguez-Vida, A;...